Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Carcinoma, Non-Small-Cell Lung 11Carcinoma, Hepatocellular 9Squamous Cell Carcinoma of Head and Neck 5Small Cell Lung Carcinoma 5Neoplasms 5Lung Neoplasms 5Colorectal Neoplasms 4Sarcoma, Alveolar Soft Part 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Solid Tumors 2Sarcoma 2Prostatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Liver Neoplasms 2Extensive Stage Lung Small Cell Carcinoma 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Unresectable Hepatocellular Carcinoma 1Stomach Neoplasms 1Small Cell Lung Cancer Extensive Stage 1Rhabdoid Tumor 1Papillary renal cell carcinoma, sporadic 1PIK3CA-Mutated Cancers 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1

Interventions

Specimen Handling 8Magnetic Resonance Spectroscopy 7Biopsy 7pembrolizumab 6Doxorubicin 6Cyclophosphamide 6X-Rays 4Radiation 4Phantoms, Imaging 4Radiotherapy 3Nuclear Medicine Department, Hospital 3Irinotecan 3Ifosfamide 3ulixertinib 2tipifarnib 2selpercatinib 2pazopanib 2palbociclib 2liposomal doxorubicin 2ivosidenib 2fludarabine 2ensartinib 2atezolizumab 2Temozolomide 2Surveys and Questionnaires 2Gemcitabine 2Fluorodeoxyglucose F18 2Carboplatin 2Bevacizumab 2trifluridine tipiracil drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Sarcoma × atezolizumab × 30 days × Clear all
NCT07049848 2026-05-22

SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma

M.D. Anderson Cancer Center

Phase 2 Recruiting
50 enrolled
Sarcoma

Sarcoma

NCT05286801 2026-05-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
86 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡